CABALETTA BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.4 USD | +16.49% |
|
-6.91% | -45.37% |
| 03-22 | HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating | MT |
| 03-21 | Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | - | Sales 2025 * | 5.56M 443M | Capitalization | 598M 47.74B |
|---|---|---|---|---|---|
| Net income 2024 * | -92M -7.34B | Net income 2025 * | -109M -8.7B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 258M 20.58B | Net cash position 2025 * | 181M 14.42B | EV / Sales 2025 * | 75.2 x |
| P/E ratio 2024 * |
-6.55
x | P/E ratio 2025 * |
-5.88
x | Employees | 102 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.49% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cabaletta Bio, Inc.
More recommendations
More press releases
| 1 day | +16.49% | ||
| 1 week | -6.91% | ||
| Current month | +16.49% | ||
| 1 month | -27.32% | ||
| 3 months | -39.45% | ||
| 6 months | -13.04% | ||
| Current year | -45.37% |
1 week
9.75
12.69
1 month
9.7519.04
Current year
9.7526.35
1 year
9.0226.35
3 years
0.5926.35
5 years
0.5926.35
10 years
0.5926.35
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 31/03/17 | |
Anup Marda
DFI | Director of Finance/CFO | 46 | 31/12/18 |
| Compliance Officer | - | 28/02/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 18/02/19 | |
| Chief Executive Officer | 62 | 31/03/17 | |
Mark Simon
BRD | Director/Board Member | 62 | 30/09/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.32% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/05/24 | 12.4 | +16.49% | 2,807,507 |
| 30/04/24 | 10.64 | +1.57% | 1,934,233 |
| 29/04/24 | 10.48 | -4.81% | 5,070,633 |
| 26/04/24 | 11.01 | -9.61% | 2,916,621 |
| 25/04/24 | 12.18 | -6.02% | 2,048,964 |
Delayed Quote Nasdaq, May 01, 2024 at 09:00 pm
More quotes
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
10.64
USD
Average target price
34.5
USD
Spread / Average Target
+224.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.37% | 514M | |
| -1.17% | 102B | |
| +2.87% | 96.09B | |
| +2.13% | 22.28B | |
| -14.77% | 21.4B | |
| -8.79% | 18.14B | |
| -39.98% | 17.02B | |
| -13.21% | 16.09B | |
| +8.55% | 13.83B | |
| +35.75% | 11.97B |
- Stock Market
- Equities
- CABA Stock
